These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 7936923)

  • 1. The anthracycline cardiotoxicity debate.
    Friedman DM
    Pediatrics; 1994 Nov; 94(5):778-9; author reply 781-2. PubMed ID: 7936923
    [No Abstract]   [Full Text] [Related]  

  • 2. The anthracycline cardiotoxicity debate.
    Silber JH
    Pediatrics; 1994 Nov; 94(5):779-80; author reply 781-2. PubMed ID: 7936924
    [No Abstract]   [Full Text] [Related]  

  • 3. The anthracycline cardiotoxicity debate.
    Barber G
    Pediatrics; 1994 Nov; 94(5):778; author reply 781-2. PubMed ID: 7936922
    [No Abstract]   [Full Text] [Related]  

  • 4. The anthracycline cardiotoxicity debate.
    Finlay J; Meadows AT
    Pediatrics; 1994 Nov; 94(5):780-1; author reply 781-2. PubMed ID: 7936925
    [No Abstract]   [Full Text] [Related]  

  • 5. Guidelines for monitoring of anthracycline cardiomyopathy: a rebuttal.
    Steinherz LJ; Graham T; Hurwitz R; Sondheimer HM; Schaffer EM; Schwartz RG; Sandor G; Benson L; Williams R
    Pediatrics; 1994 Nov; 94(5):782-4. PubMed ID: 7936926
    [No Abstract]   [Full Text] [Related]  

  • 6. Anthracycline associated cardiac toxicity in children with malignancies.
    Mohta R; Saxena A; Jain Y; Gupta S; Thavaraj V; Narain S; Arya LS
    Indian Pediatr; 2002 Jun; 39(6):549-55. PubMed ID: 12084948
    [No Abstract]   [Full Text] [Related]  

  • 7. [Cardiotoxicity in anthracycline chemotherapy: significance of infusion durations. Analysis of a Cochrane review].
    Appel JM; Rybjerg M; Nielsen DL
    Ugeskr Laeger; 2007 Sep; 169(37):3105-7. PubMed ID: 17877960
    [No Abstract]   [Full Text] [Related]  

  • 8. [Anthracycline cardiotoxicity: review].
    Ribera JM; Montserrat E; Rozman C
    Sangre (Barc); 1983; 28(1):54-68. PubMed ID: 6346540
    [No Abstract]   [Full Text] [Related]  

  • 9. [Cardiotoxicity of anthracycline].
    Wojtukiewicz MZ; Omyła J; Kozłowski L; Szynaka B
    Postepy Hig Med Dosw; 2000; 54(4):467-85. PubMed ID: 11016267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anthracycline-induced heart failure.
    van Dalen EC
    Nat Clin Pract Oncol; 2007 Dec; 4(12):E1. PubMed ID: 18037871
    [No Abstract]   [Full Text] [Related]  

  • 11. Detection of anthracycline-induced cardiotoxicity.
    Meinardi MT; van der Graaf WT; van Veldhuisen DJ; Gietema JA; de Vries EG; Sleijfer DT
    Cancer Treat Rev; 1999 Aug; 25(4):237-47. PubMed ID: 10448132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anthracycline cardiotoxicity and its prevention.
    Mott MG
    Ann N Y Acad Sci; 1997 Sep; 824():221-8. PubMed ID: 9382447
    [No Abstract]   [Full Text] [Related]  

  • 13. Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (review).
    Orditura M; Quaglia F; Morgillo F; Martinelli E; Lieto E; De Rosa G; Comunale D; Diadema MR; Ciardiello F; Catalano G; De Vita F
    Oncol Rep; 2004 Sep; 12(3):549-56. PubMed ID: 15289836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anthracycline-induced cardiotoxicity: comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials.
    van Dalen EC; van den Brug M; Caron HN; Kremer LC
    Eur J Cancer; 2006 Dec; 42(18):3199-205. PubMed ID: 17011186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy.
    Pinarli FG; Oğuz A; Tunaoğlu FS; Karadeniz C; Gökçora N; Elbeg S
    Pediatr Blood Cancer; 2005 Apr; 44(4):370-7. PubMed ID: 15602715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of anthracyclines in the era of targeted therapy.
    Cortés-Funes H; Coronado C
    Cardiovasc Toxicol; 2007; 7(2):56-60. PubMed ID: 17652804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention--review of the literature.
    Wojtacki J; Lewicka-Nowak E; Leśniewski-Kmak K
    Med Sci Monit; 2000; 6(2):411-20. PubMed ID: 11208348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anthracyclines: cardiotoxicity and its prevention.
    Hale JP; Lewis IJ
    Arch Dis Child; 1994 Nov; 71(5):457-62. PubMed ID: 7826122
    [No Abstract]   [Full Text] [Related]  

  • 19. [Noninvasive evaluation of anthracycline cardiotoxicity].
    Mladosievicová B; Foltinová A; Bernadic M; Hubka P; Puskacová J; Petrásová H; Hulín I
    Bratisl Lek Listy; 1998 Jan; 99(1):60-2. PubMed ID: 9634287
    [No Abstract]   [Full Text] [Related]  

  • 20. Serum carnitine levels during the doxorubicin therapy. Its role in cardiotoxicity.
    Yaris N; Ceviz N; Coskun T; Akytüz C; Büyükpamukçu M
    J Exp Clin Cancer Res; 2002 Jun; 21(2):165-70. PubMed ID: 12148572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.